Health Care • Biotechnology: Pharmaceutical Preparations
$12.25 ▼ -0.03
(-0.24%)
MKT CAP: $216.1M • VOL: 99.4K
52W L $12 52W H $28
NATR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $480.1M | $454.4M | $445.3M |
| YoY Revenue Growth % | +5.7% | +2.0% | — |
| Gross Profit | $347.7M | $324.7M | — |
| Gross Margin % | 72.4% | 71.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $24.7M | $20.1M | $18.7M |
| Operating Margin % | 5.2% | 4.4% | 4.2% |
| Net Income (GAAP) | $19.5M | $7.7M | $15.1M |
| EBITDA (Normalized) | $29.9M | $28.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $35.3M | $25.3M | $41.2M |
| Capital Expenditures (CapEx) | $6.5M | $11.0M | — |
| Free Cash Flow (FCF) | $28.8M | $14.3M | $41.2M |
| FCF Margin % | 6.0% | 3.2% | 9.3% |
| Return on Invested Capital (ROIC %) | 28.9% | 20.8% | — |
| Cash & Short-Term Equivalents | $93.9M | $84.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $161.6M | $161.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NATR.